An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Tamura, Tomohide [1 ]
Nishio, Makoto [2 ]
Yamamoto, Nobuyuki [3 ]
Ohe, Yuichiro [1 ]
Wolff, Katharina [4 ]
Tsujimoto, Mika [5 ]
Enatsu, Sotaro [4 ]
Nakagawa, Kazuhiko [6 ]
机构：
[1] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[2] Canc Inst Hosp Jfcr, Thorac Med Oncol, Tokyo, Japan
[3] Wakayama Med Univ Hosp, Med Oncol, Wakayama, Japan
[4] Eli Lilly Japan, Med Sci, Kobe, Hyogo, Japan
[5] Eli Lilly Japan, Stat Sci, Kobe, Hyogo, Japan
[6] Kinki Univ, Fac Med, Med Oncol, Osaka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
gemcitabine-cisplatin; necitumumab; squamous non-small cell lung cancer; trial in progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-080
引用
收藏
页码：S664 / S665
页数：2
相关论文
共 50 条
  • [1] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase lb and randomized, open-label, multicenter, phase 2 trial in Japan
    Watanabe, Satoshi
    Yoshioka, Hiroshige
    Sakai, Hiroshi
    Hotta, Katsuyuki
    Takenoyama, Mitsuhiro
    Yamada, Kazuhiko
    Sugawara, Shunichi
    Takiguchi, Yuichi
    Hosomi, Yukio
    Tomii, Keisuke
    Niho, Seiji
    Yamamoto, Nobuyuki
    Nishio, Makoto
    Ohe, Yuichiro
    Kato, Terufumi
    Takahashi, Toshiaki
    Kamada, Ami
    Suzukawa, Kazumi
    Omori, Yukie
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    Tamura, Tomohide
    LUNG CANCER, 2019, 129 : 55 - 62
  • [2] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan (vol 129, pg 55, 2019)
    Watanabe, Satoshi
    Yoshioka, Hiroshige
    Sakai, Hiroshi
    Hotta, Katsuyuki
    Takenoyama, Mitsuhiro
    Yamada, Kazuhiko
    Sugawara, Shunichi
    Takiguchi, Yuichi
    Hosomi, Yukio
    Tomii, Keisuke
    Niho, Seiji
    Yamamoto, Nobuyuki
    Nishio, Makoto
    Ohe, Yuichiro
    Kato, Terufumi
    Takahashi, Toshiaki
    Kamada, Ami
    Suzukawa, Kazumi
    Omori, Yukie
    Enatsu, Sotaro
    Nakagawa, Kazuhiko
    Tamura, Tomohide
    LUNG CANCER, 2019, 132 : 157 - 158
  • [3] Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
    Park, Keunchil
    Cho, Eun Kyung
    Bello, Maximino
    Ahn, Myung-Ju
    Thongprasert, Sumitra
    Song, Eun-Kee
    Soldatenkova, Victoria
    Depenbrock, Henrik
    Puri, Tarun
    Orlando, Mauro
    CANCER RESEARCH AND TREATMENT, 2017, 49 (04): : 937 - 946
  • [4] A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
    Besse, B.
    Barlesi, F.
    Demedts, I.
    Fuentes Pradera, J.
    Renault, A.
    Robinet, G.
    Frimodt-Moller, B.
    Gil, M.
    Vansteenkiste, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S76 - S76
  • [5] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    Thatcher, Nick
    Hirsch, Fred R.
    Luft, Alexander V.
    Szczesna, Aleksandro
    Ciuleanu, Tudor E.
    Dediu, Mircea
    Ramlau, Rodryg
    Galiulin, Rinat K.
    Balint, Beatrix
    Losonczy, Gyoergy
    Kazarnowicz, Andrzej
    Park, Keunchil
    Schumann, Christian
    Reck, Martin
    Depenbrock, Henrik
    Nanda, Shivani
    Letunic, Anamarija Kruljac
    Kurek, Raffacl
    Paz-Ares, Luis
    Socinskf, Mark A.
    LANCET ONCOLOGY, 2015, 16 (07): : 763 - 774
  • [6] A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
    Besse, Benjamin
    Barlesi, Fabrice
    Demedts, Ingel
    Pradera, Jose Fuentes
    Robinet, Gilles
    Gazzah, Anas
    Soldatenkova, Victoria
    Frimodt-Moller, Bente
    Kim, Jong Seok
    Vansteenkiste, Johan
    LUNG CANCER, 2019, 137 : 136 - 143
  • [7] A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC)
    Socinski, M.
    Gil, M.
    Shahidi, J.
    Chao, G. Y.
    Villaruz, L.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer
    Sandler, Alan
    Graham, Charles
    Baggstrom, Maria
    Herbst, Roy
    Zergebel, Christopher
    Saito, Kaku
    Jones, Dennie
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (08) : 1400 - 1406
  • [9] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [10] Phase 1b expansion cohort study to evaluate the safety and efficacy of necitumumab and abemaciclib combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
    Besse, B.
    Barlesi, F.
    Ceccarelli, M.
    Chao, G. Y.
    Frimodt-Moller, B.
    Gil, M.
    Vansteenkiste, J.
    ANNALS OF ONCOLOGY, 2016, 27
12345